# A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation

> **NCT07678593** · PHASE1,PHASE2 · RECRUITING · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 222 (estimated)

## Conditions studied

- Advanced Solid Tumors Cancer
- Pancreatic Ductal Adenocarcinoma
- RAS Mutation

## Interventions

- **DRUG:** GFH276
- **DRUG:** Cetuximab
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT07678593
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2027-11
- **Final completion:** 2028-09
- **Target enrollment:** 222 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07678593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07678593, "A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07678593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*